Dermatology News and Research

Latest Dermatology News and Research

MedWorks and its partners to offer two days of free cancer screenings

On Saturday, June 2, and Sunday, June 3, 2012, MedWorks, its partners The Free Medical Clinic of Greater Cleveland, University Hospitals Seidman Cancer Center and the Cleveland Clinic-Taussig Cancer Center, and volunteers will provide two days of free cancer screenings at a MedWorks clinic held at The Free Medical Clinic of Greater Cleveland, 12201 Euclid Avenue, Cleveland, Ohio 44106.

17 May 2012

Early skin cancer detection with digital dermoscopy

FotoFinder presents advanced devices for early skin cancer detection at the World Congress of Dermoscopy in Brisbane from May 17 to 19. The new mobile and stationary devices offer better diagnostic accuracy for doctors and more safety for patients. Latest development is the connection of a mobile dermatoscope for iPhone with an online webspace where doctors can request a second opinion on suspicious moles.

17 May 2012

Data from Jennerex JX-594 clinical trials on cancer to be presented at ASCO annual meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer will be covered in three separate abstracts released today by the American Society of Clinical Oncology.

17 May 2012

National Psoriasis Foundation awards more than $2 million for research

Twenty-six scientists have received a total of $2.06 million in grants from the National Psoriasis Foundation to study psoriasis—the most common autoimmune disease in the country, affecting as many as 7.5 million Americans—and psoriatic arthritis, an inflammatory joint and tendon disease.

16 May 2012

AAD reiterates safety and effectiveness of sunscreens against UV radiation

The American Academy of Dermatology (Academy) today reiterated the safety and effectiveness of sunscreens to protect against the damaging effects from exposure to ultraviolet (UV) radiation.

16 May 2012

Many men do not protect their skin from sun exposure

As everyone knows, growing older brings an increased number of health concerns. In fact, dermatologists warn that men older than 50 have an increased risk of developing melanoma - the deadliest form of skin cancer.

15 May 2012

Many young adults not aware of tanning bed dangers

Despite the fact that young adults are generally in constant communication via social media and texting, a new survey finds many in this age group are not getting the message that there is no such thing as a safe tan.

15 May 2012

College Park Family Care Center chooses eClinicalWorks comprehensive EHR solution

eClinicalWorks, a market leader in ambulatory clinical systems, today announces that College Park Family Care Center, the largest non-hospital owned multi-specialty group in the Kansas City-area, has chosen eClinicalWorks comprehensive electronic health records (EHR) solution for its 91 providers across 12 locations.

14 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

Preclinical evidence demonstrates link between psoriasis and cardiovascular disease

The link between psoriasis and cardiovascular events has been observed for years, however the mechanics were unknown. For the first time, Case Western Reserve University School of Medicine researchers have discovered preclinical evidence demonstrating that the inflammatory skin disease leads to cardiovascular disease. Further, the research demonstrated that aggressive reversal of psoriasis reduces the cardiovascular risk as well.

11 May 2012

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

Dead skin donors come to the aid of a 92 year old with severe skin ulcers

A great grandmother is the first person in Britain to have a wound healed using skin from dead donors.

9 May 2012

More teenagers and young adults diagnosed with skin cancer

With summer just around the corner, pediatricians at Johns Hopkins Children's Center are sounding the alarm on a disturbing trend: A growing number of teenagers and young adults diagnosed with skin cancer.

8 May 2012

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. entered into a co-promotion agreement for EYLEA aflibercept) Injection in Japan.

From Santen Pharmaceutical Co., Ltd. 8 May 2012

MD Anderson dermatologists applaud upcoming FDA changes to sunscreen labels

Sunscreen labels can be confusing and at times misleading. That's why dermatologists at The University of Texas MD Anderson Cancer Center applaud the upcoming U.S. Food and Drug Administration (FDA) label changes that help consumers understand exactly what they're buying.

8 May 2012

Survey: Many people do not know how to spot skin cancer

Doing a little detective work can go a long way in finding skin cancer, the most common form of cancer diagnosed in the United States, at its earliest, most treatable stage. However, a new survey found that many people do not know how to spot skin cancer and are unaware of their risk of developing the disease.

8 May 2012

Halozyme first quarter net loss increases to $15.1 million

Halozyme Therapeutics, Inc. today reported financial results for the quarter ended March 31, 2012.

8 May 2012

Nuvo receives BfArM positive opinion for Pliaglis

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain and the development of its immune modulating drug candidate WF10, today announced that it has received notice of a positive opinion from the European Decentralized Procedure for the approval of Pliaglis from the German Federal Institute for Drugs and Medical Devices (BfArM), the reference member state.

7 May 2012

KYTHERA ATX-101-10-16 trial for submental fat meets primary endpoints

KYTHERA Biopharmaceuticals, Inc. today announced the presentation of initial trial results from Study ATX-101-10-16, the first of two pivotal European Phase III clinical trials with ATX-101, a facial injectable drug for the reduction of unwanted fat under the chin, or submental fat.

7 May 2012

Clinical data from Anacor’s tavaborole and AN2728 study to be presented at upcoming meetings

Anacor Pharmaceuticals announced today that it will be presenting clinical data on its lead compounds, tavaborole and AN2728, at the following upcoming medical meetings.

5 May 2012